Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone
- PMID: 3485123
- DOI: 10.1097/00004728-198603000-00001
Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone
Abstract
Two patients with pituitary tumors were examined with positron emission tomography (PET) after intravenous administration of 11C-N-methylspiperone. In repeat studies the patients were given 1 mg of intravenous haloperidol prior to the administration of the radioligand to block the dopamine receptors. High uptakes of the radiolabeled ligand were seen in one of the tumors. With haloperidol pretreatment the uptake was lower, probably mainly showing the remaining unspecific binding. The most marked uptake and the largest effect of haloperidol pretreatment was seen in a patient with a hormonally active prolactinoma. Dopamine receptor binding in pituitary tumors can be demonstrated in vivo with PET, and quantification of this binding is possible using a compartmental model. This technique may be useful in improving our understanding of the variable response to medical treatment of prolactinomas with dopamine agonists as well as in the prediction of the effect of such treatment.
Similar articles
-
Positron emission tomography applied in the study of pituitary adenomas.J Endocrinol Invest. 1991 Jun;14(6):509-28. doi: 10.1007/BF03346855. J Endocrinol Invest. 1991. PMID: 1837798 Review. No abstract available.
-
In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography.Acta Radiol Suppl. 1986;369:406-8. Acta Radiol Suppl. 1986. PMID: 2980511
-
[Clinical application of 11C-NMSP to the patients with pituitary adenoma other than prolactinoma].Kaku Igaku. 1993 Jun;30(6):627-35. Kaku Igaku. 1993. PMID: 8345693 Japanese.
-
Positron emission tomography in acromegaly and other pituitary adenoma patients.Neuroendocrinology. 2006;83(3-4):205-10. doi: 10.1159/000095529. Neuroendocrinology. 2006. PMID: 17047384 Clinical Trial.
-
Diagnostic imaging of dopamine receptors in pituitary adenomas.Eur J Endocrinol. 2007 Apr;156 Suppl 1:S53-S56. doi: 10.1530/eje.1.02349. Eur J Endocrinol. 2007. PMID: 17413189 Review.
Cited by
-
Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding.J Neural Transm Gen Sect. 1990;79(3):215-26. doi: 10.1007/BF01245132. J Neural Transm Gen Sect. 1990. PMID: 2137000
-
Positron emission tomography applied in the study of pituitary adenomas.J Endocrinol Invest. 1991 Jun;14(6):509-28. doi: 10.1007/BF03346855. J Endocrinol Invest. 1991. PMID: 1837798 Review. No abstract available.
-
18F-fallypride and 11C-methionine positron emission tomography/computed tomography for the study of prolactinomas and nonfunctioning pituitary adenomas: A case series.World J Nucl Med. 2021 Mar 15;20(3):286-293. doi: 10.4103/wjnm.WJNM_83_20. eCollection 2021 Jul-Sep. World J Nucl Med. 2021. PMID: 34703398 Free PMC article.
-
Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats.Onco Targets Ther. 2016 Apr 6;9:2057-68. doi: 10.2147/OTT.S94057. eCollection 2016. Onco Targets Ther. 2016. PMID: 27103832 Free PMC article.
-
Where have we got to with neuroreceptor mapping of the human brain?Eur J Nucl Med. 1990;16(11):817-35. doi: 10.1007/BF00833018. Eur J Nucl Med. 1990. PMID: 2170141 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical